BRD3731

BRD3731

B646260-5mg

5mg

≥98%

-20°C储存

超低温冰袋运输

BRD3731 is a selective GSK3β inhibitor, with IC 50 s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731 is potentail for the research of post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorders In Vitro BRD3731 is a GSK3β- selective inhibitor extracted from patent US20160375006A1, compound example 272. BRD3731 (1-10 μM; 24 hours) inhibits the phosphorylation of CRMP2 in SH-SY5Y cells. BRD3731 (20 μM; 24 hours) decreases β-catenin S33/37/T41 phosphorylation and induces β-catenin S675 phosphorylation in HL-60 cells. BRD3731 (10-20 μM; 7-10 days) impairs colony formation in TF-1 and increases colony forming ability in the MV4-11 cell lineMCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:GSK-3β 15 nM (IC 50 ) GSK-3α 215 nM (IC 50 )

BRD3731 是一种选择性 GSK3β 抑制剂，对 GSK3β 和 GSK3α 的 IC 50 s 分别为 15 nM 和 215 nM。BRD3731 可用于研究创伤后应激障碍（PTSD）、精神障碍、糖尿病和神经退行性疾病。

2056262-07-6

C24H31N3O

377.52 g/mol

135567205

(4S)-3-(2,2-dimethylpropyl)-4,7,7-trimethyl-4-phenyl-2,6,8,9-tetrahydropyrazolo[3,4-b]quinolin-5-one

1S/C24H31N3O/c1-22(2,3)12-17-20-21(27-26-17)25-16-13-23(4,5)14-18(28)19(16)24(20,6)15-10-8-7-9-11-15/h7-11H,12-14H2,1-6H3,(H2,25,26,27)/t24-/m1/s1

YZRXTIGAQRIAEX-XMMPIXPASA-N

CC1(CC2=C(C(=O)C1)C(C3=C(NN=C3N2)CC(C)(C)C)(C)C4=CC=CC=C4)C

135567205

DMSO : 50 mg/mL (132.44 mM; Need ultrasonic)